Dyne Therapeutics sharpens case for two muscle disease therapies with updated...
Dyne Therapeutics shared promising clinical trial updates from two of its experimental RNA medicines for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy. The update, announced Monday,...
View ArticleUpdated: Lobbying group BIO restructures staff in shakeup under new CEO
The trade group BIO has parted ways with 30 employees, including several senior leaders, in what sources are describing as a restructuring of the trade organization, the latest changes at the...
View ArticleFDA approves first two interchangeable biosimilars to Regeneron's blockbuster...
Eylea will eventually have competition in the US, as the FDA approved two interchangeable biosimilars. Monday’s approvals for Biocon Biologics’ Yesafili and Samsung Bioepis and Biogen’s Opuviz are...
View ArticleEuropean Commission declines CHMP's negative opinion on muscular dystrophy drug
The European Commission made the rare decision Monday not to adopt the negative opinion of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on the renewal of...
View ArticleJury says AstraZeneca should pay Pfizer $107M+ over Tagrisso infringement
A federal jury in Delaware determined that AstraZeneca infringed two Pfizer patents with its blockbuster cancer treatment Tagrisso, and that the British drugmaker should pay $107.5 million as a result....
View ArticleExclusive: Members of Congress buy and sell stocks that would gain from bill...
At least seven members of Congress since 2023 have bought and sold stocks of life science companies that would gain from legislation to ban several key Chinese biotech suppliers and contractors,...
View ArticleFDA withdraws Helsinn’s accelerated approval for cancer drug after company’s...
The FDA on Friday withdrew an accelerated approval for Helsinn’s bile duct cancer drug, two years after the company couldn’t complete its confirmatory trial and requested that the FDA withdraw...
View ArticleLabGenius raises £35M to develop solid tumor drugs based on machine learning
LabGenius has secured £35 million ($44.5 million) in a Series B raise to expand its antibody discovery platform and advance a pipeline of cancer candidates. The UK biotech will use the same machine...
View ArticleGSK says long-acting asthma treatment depemokimab clears two Phase 3 studies
GSK announced Tuesday morning that its experimental antibody treatment reduced the yearly rate of asthma attacks across two key clinical trials for adolescents and adults with a form of severe asthma....
View ArticleADC biotech Pheon raises $120M to test three assets in the clinic
Investors continue to flock toward antibody-drug conjugates. Pheon Therapeutics is the latest to catch the tailwinds of the booming segment of oncology R&D. The London-based startup disclosed a...
View ArticleClik here to view.
AstraZeneca targets $80B revenue, 20 new drugs by 2030
AstraZeneca on Tuesday morning unveiled its ambitious plan to be one of the fastest growing pharma companies by the end of the decade. In what CEO Pascal Soriot described as “a new era of growth,” the...
View ArticleClik here to view.
FDA lifts partial clinical hold on Larimar’s Friedreich’s ataxia treatment
Larimar Therapeutics’ stock $LRMR shot up by as much as 20% after announcing Monday that the FDA had lifted its partial clinical hold on its treatment for Friedreich’s ataxia, a rare disorder that...
View ArticleClik here to view.
Lilly makes another radiopharma move in collaboration with Aktis Oncology
Eli Lilly is again dipping into the buzzy area of radiopharmaceuticals by way of private biotech Aktis Oncology. The pharma giant will dish out $60 million upfront and make an undisclosed equity...
View ArticleAltruBio secures $225M for an updated version of its ulcerative colitis drug
Bay Area and Taipei biotech AltruBio has raised $225 million in a Series B to move forward its experimental drug for ulcerative colitis and other chronic autoimmune conditions, it said Tuesday. The...
View ArticleAI biotech Exscientia to trim nearly a quarter of workforce, following...
Exscientia announced a $40 million cost-saving program on Tuesday that will lead to layoffs affecting 20% to 25% of the company’s workers. The move, disclosed as part of a first-quarter update Tuesday...
View ArticleClik here to view.
Sanofi, OpenAI, Formation Bio announce AI drug development partnership
French pharmaceutical giant Sanofi will work with the tech powerhouse OpenAI and New York-based startup Formation Bio to develop AI-powered software in drug R&D, the three companies announced...
View ArticleClik here to view.
With a fresh $100M, Monte Rosa CEO details plans to move several molecular...
Monte Rosa Therapeutics CEO Markus Warmuth expects molecular glues to make up a new class of drugs with “almost unlimited potential” in the long run, allowing scientists to tackle disease-causing...
View ArticleLyra to lay off 75% of its workers; Dupixent nears COPD decision
Plus, news about BioNTech, Medigene, YGION Biomedical, Eli Lilly and Alloy Therapeutics: Lyra lays off 87 employees: The Watertown, MA-based biotech will let go of 75% of its workforce, stop...
View ArticleAstraZeneca outlines growth plans for 2030 and beyond with focus on...
CAMBRIDGE, UK — Pascal Soriot has set an ambitious $80 billion revenue target for AstraZeneca by 2030. But he’s not stopping there. At the drugmaker’s Discovery Centre in Cambridge, UK, the CEO,...
View ArticleClik here to view.
Hims’ push into compounded GLP-1 drugs risks scrutiny from Novo Nordisk
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The digital health company Hims & Hers has started prescribing a cheaper, compounded version of a...
View Article